Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
EXBLIFEP (CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
EXBLIFEP
NDA
Get alerts
CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM | N216165 | ORCHID PHARMA LTD
1 strength
2 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
2 unique patents, 2 exclusivities by expiration date
Active (2)
Today
Exclusivity
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
7687488
Dec. 3, 2027
11124526
Nov. 7, 2034
NCE
Feb. 22, 2029
GAIN
Feb. 22, 2034
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 2GM BASE/VIAL;0.5GM/VIAL
RLD
2 patents
2 exclusivities
▴
POWDER;INTRAVENOUS | Approved: Feb 22, 2024
Patents (2)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
7687488
Dec 3, 2027
—
Yes
Yes
U-3851
USE OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS
—
11124526
Nov 7, 2034
—
—
—
U-3852
USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS
—
Exclusivities (2)
Code
Date
Status
GAIN
Feb 22, 2034
Active
NCE
Feb 22, 2029
Active